Editorial Jottings on an Old Blotter
One has heard a number of anaesthetists say that in Australia the specialty enjoys a particularly good relationship with the trade (meaning the pharmaceutical and instrument manufacturers and distributors). It is most desirable that such a relationship exists because it is arguable that after the anaesthetist the most important party in contributing to the safety of anaesthesia is 'the trade'.
This good relationship has procured many benefits for our patients. Direct and frank communication has helped iron out problems with equipment to the benefit of all parties. The costs of scientific and clinical meetings have been partly defrayed by money spent by the trade in mounting displays. Research has been funded by grants from industry. The CIG Medishield Award, the Boots Young Investigator Awards and the Janssen Pharmaceutical ASA Research Fellowship are fine examples of industry making a positive and liberal contribution to research in anaesthesia in Australia. The production of this very journal is facilitated by its attracting advertising.
The position has not been reached in our specialty in Australia where whole departments have been funded by drug or equipment companies. There are definite advantages in the status quo. At times when listening to speakers from such departments abroad one had felt a raw nerve of Australian scepticism being tickled.
In the 'fifties it was common for pharmaceutical company representatives to leave ink blotters embellished with the names of company products with G.P.'s when they called on them. They were a great hit with the doctors' children who would swap them for 'dibs', sweets, etc. Such innocence. And yet in retrospect it represented the start of a progression which has elsewhere culminated in physicians being shown to be most blatently compromised in accepting gifts from pharmaceutical companies. I.2 In 1986 the Royal Australasian College of Physicians issued a statement entitled 'A Guide to ethical principles in the relationship between physicians and the pharmaceutical industry'. The Royal College of Physicians has also issued a similar report. 3 The following three areas of concern are covered in detail in the Australasian document. • Ethical principles in the conduct of clinical trials including commissioned research projects. • Pharmaceutical industry sponsored travel. • Guidelines for the conduct of supported meetings. These documents appear not to have been widely read by anaesthetists, but deserve to be, for they deal with ethical issues which we need to consider as individuals and at departmental and national level. Where individuals and departments are concerned the need for research projects involving new equipment or drugs to have Ethics Committee approval before they are commenced is an important safeguard against abuse. It goes without saying the Ethics Committees must be rigorous in performing their task and be appropriately constituted.
When travel, the funding of overseas speakers, and funding of meetings are concerned is it not time that those organising national and regional meetings had guidelines defining what is acceptable support in these matters, and what is not? The statement by the two Colleges of Physicians could well serve as a basis for discussion in the development of such guidelines. At major meetings on anaesthetics in the past there has been a very clear distinction between the clinical and scientific program and the trade exhibition. It is vitally important to the specialty, the trade, and, most importantly, to the public that this should remain so.
Thus it is hoped that in the future we will still be able to describe relations between our speciaity and industry as being 'good'.
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